MPs condemn NHS rollout of Mounjaro as limited and deepening health inequality
MPs say the NHS plan to provide the weight-loss drug Mounjaro will reach only about 6% of eligible patients, creating a two-tier system.
A report from the Commons Health and Social Care Committee slammed the NHS’s slow, phased rollout of the GLP-1 weight-loss medication Mounjaro, estimating that just 6% of the 2.8 million eligible patients will be treated within three years. MPs argued the approach creates a two-tier system where most patients must turn to private providers, exacerbating obesity-related health inequalities. They urged the government to accelerate the programme, use digital-provider capacity, and convene a summit with clinicians and suppliers to improve access.
The committee also called for obesity to be managed like diabetes, better data sharing between GPs and prescribers, and a review of the MHRA’s resources to combat illegal GLP-1 trade. Additional concerns were raised about long waiting times for specialised clinics for children with obesity. Stakeholders such as the National Pharmacy Association and LloydsPharmacy Online Doctor highlighted the risk of a black market and the upcoming expiry of semaglutide patents.
Why it matters
Limited NHS access to effective weight-loss drugs leaves most patients to pay privately, widening health inequality.
How the sides frame it
HIGH AGREEMENTBoth camps report the same committee findings, but centrist coverage frames the story as MPs urging broader access and labeling the plan "woefully small" and "unambitious," while right-leaning coverage frames it as a condemned, limited rollout that deepens health inequality and calls for government acceleration.
CENTER
Centrist coverage presents MPs urging expanded access and criticises centrist coverage plan as "woefully small" and "unambitious," highlighting a nascent two-tier system.
RIGHT
Right-leaning coverage condemns the rollout as limited and inequality-deepening, urging faster government action and systemic reforms.
The right emphasises
- limited rollout
- deepening health inequality
- urge government to accelerate the programme
In this story
